Vical Incorporated Licensee Sanofi-Aventis (France) Completes Enrollment in Phase 3 Angiogenesis Trial
SAN DIEGO, Sept. 28, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company's licensee, sanofi-aventis, has confirmed the completion of enrollment in a multinational 500-patient pivotal Phase 3 clinical trial of its angiogenesis therapy based on Vical's non-viral DNA delivery technology. Sanofi-aventis expects final data from this trial in late 2010.